Fagron NV (FAGR) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
October 2018
42
About the Report
About the Report
Summary
Fagron NV (Fagron), formerly Arseus NV is a pharmaceutical compounding solution provider. The company offers products such as raw materials, extracts and tinctures, flammable products, anesthesia, ointment bases, syrups, suspension media, triturations, phyto pharmaflore, medispend, capsicards system, capsicards gelulen and consumables. It also offers dispensers, liquid preparations, semi-solid preparations, solid preparations, piluliers, pumps and consumables, among others. Fagron's compounding services provide customized pharmaceutical products for specific patient needs. The company's products find its application in therapeutic areas such as allergy, antibiotic, skin, and others. Fagron is headquartered in Nazareth, Belgium.
Fagron NV (FAGR)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.
GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.
Scope
- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.
- Business Description-A brief description of the company's operations.
- Key Employees-A list of the key executives of the company.
- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors-A list of the key competitors of the company.
- Key Recent Developments-A brief on recent news about the company.
Reasons to Buy
Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.
Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.
Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.
Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.
Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.
Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.
Note*: Some sections may be missing if data is unavailable for the company.
Products
Products
Fagron NV, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.
Table of Contents
Table of Contents
Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 10
Fagron NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fagron NV, Pharmaceuticals & Healthcare, Deal Details 12
Asset Purchase 12
Fagron Acquires Four Compounding Pharmacies From Quifarma 12
Partnerships 13
Fagron Enters Into Joint Venture With NxGen Pharma To Form Fagron Australia 13
Licensing Agreements 14
Omeros Enters into Licensing Agreement with Fagron 14
Equity Offering 15
Fagron Raises USD96.7 Million in Rights Offering of Shares 15
Fagron to Raise up to USD99 Million in Rights Offering of Shares 16
Fagron Raises USD147 Million in First Tranche of Private Placement of Shares 17
Fagron Raises USD10 Million in Public Offering of Shares 19
Fagron Completes Private Placement of Shares upon Exercise of Warrants 20
Debt Offering 21
Fagron Raises USD297.3 Million in Public Offering of Bonds 21
Acquisition 22
Fagron to Acquire Humco for USD70 Million 22
Fagron Acquires All Chemistry 23
Fagron to Acquire AnazaoHealth 24
Gilde Healthcare Sells its Stake in Pharmaline 25
Waterland Divests 26.67% Stake In Arseus 26
Fagron Acquires JCB Labs 27
Fagron Acquires Freedom Pharma 28
Fagron To Acquire B&B Pharma 29
Fagron Acquires Orbus Pharma, Drug Manufacturing Company 30
Fagron Acquires ApodanNordic PharmaPackaging, Provider Of Pharma Packaging Solutions 31
Fagron Acquires Florien, Medical Products Distributor 32
Fagron NV-Key Competitors 33
Fagron NV-Key Employees 34
Fagron NV-Locations And Subsidiaries 35
Head Office 35
Other Locations & Subsidiaries 35
Recent Developments 38
Financial Announcements 38
Oct 11, 2018: Fagron continues strong turnover growth of first semester in the third quarter of 2018 38
Aug 03, 2018: Fagron realised organic turnover growth of 8.5% 40
Corporate Communications 41
Nov 27, 2017: Fagron: Rafael Padilla succeeds Hans Stols as CEO 41
Appendix 42
Methodology 42
About GlobalData 42
Contact Us 42
Disclaimer 42
List of Figure
List of Figures
Fagron NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fagron NV, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 10
List of Table
List of Tables
Fagron NV, Pharmaceuticals & Healthcare, Key Facts, 2017 2
Fagron NV, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6
Fagron NV, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7
Fagron NV, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8
Fagron NV, Deals By Therapy Area, 2012 to YTD 2018 9
Fagron NV, Medical Devices Deals, 2012 to YTD 2018 10
Fagron NV, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11
Fagron Acquires Four Compounding Pharmacies From Quifarma 12
Fagron Enters Into Joint Venture With NxGen Pharma To Form Fagron Australia 13
Omeros Enters into Licensing Agreement with Fagron 14
Fagron Raises USD96.7 Million in Rights Offering of Shares 15
Fagron to Raise up to USD99 Million in Rights Offering of Shares 16
Fagron Raises USD147 Million in First Tranche of Private Placement of Shares 17
Fagron Raises USD10 Million in Public Offering of Shares 19
Fagron Completes Private Placement of Shares upon Exercise of Warrants 20
Fagron Raises USD297.3 Million in Public Offering of Bonds 21
Fagron to Acquire Humco for USD70 Million 22
Fagron Acquires All Chemistry 23
Fagron to Acquire AnazaoHealth 24
Gilde Healthcare Sells its Stake in Pharmaline 25
Waterland Divests 26.67% Stake In Arseus 26
Fagron Acquires JCB Labs 27
Fagron Acquires Freedom Pharma 28
Fagron To Acquire B&B Pharma 29
Fagron Acquires Orbus Pharma, Drug Manufacturing Company 30
Fagron Acquires ApodanNordic PharmaPackaging, Provider Of Pharma Packaging Solutions 31
Fagron Acquires Florien, Medical Products Distributor 32
Fagron NV, Key Competitors 33
Fagron NV, Key Employees 34
Fagron NV, Subsidiaries 35
Why Buy From US?
What makes us stand out is that our consultants follows Robust, Refine and Result (RRR) methodology. i.e. Robust for clear definitions, approaches and sanity checking, Refine for differentiating respondents facts and opinions and Result for presenting data with story
We have set a benchmark in the industry by offering our clients with syndicated and customized market research reports featuring coverage of entire market as well as meticulous research and analyst insights.
While we don't replace traditional research, we flip the method upside down. Our dual approach of Top Bottom & Bottom Top ensures quality deliverable by not just verifying company fundamentals but also looking at the sector and macroeconomic factors.
With one step in the future, our research team constantly tries to show you the bigger picture. We help with some of the tough questions you may encounter along the way: How is the industry positioned? Best marketing channel? KPI's of competitors? By aligning every element, we help maximize success.
Our report gives you instant access to the answers and sources that other companies might choose to hide. We elaborate each steps of research methodology we have used and showcase you the sample size to earn your trust.
If you need any support, we are here! We pride ourselves on universe strength, data quality, and quick, friendly, and professional service.